Introduction
============

Lithium has been the treatment of choice for bipolar disorder (BD) for many years. It works particularly well with BD because it is efficient both as a prophylactic and as an acute treatment; in addition, it has been successfully used as an augmenting agent in the management of unipolar depression. Given the debilitating nature of BD, its lifetime prevalence and significant occurrence in the general population (1 to 2%), understanding the mode of action of one of its most efficient lines of treatments is critical \[[@B1],[@B2]\].

Lithium can be highly effective, but unfortunately only a subset of patients responds well to this treatment. These patients are distinguishable from non-responders through a number of clinical characteristics that appear to be accounted for, to a certain extent, by the individual\'s genetic makeup. For instance, BD patients with positive response to lithium typically suffer from a non-rapid cycling course of illness with full remission between episodes \[[@B3]\]. Patients with a family history of lithium-responsive BD among first-degree relatives have a better chance of responding well to lithium \[[@B4]\]. This adds evidence for the heritability of the response to prophylactic treatment with lithium, a fact that can be used in the design of experiments aimed at deciphering the complex etiology of BD as well as the mode of action of lithium treatment.

In this paper, we will review clinical and molecular studies that characterize lithium response in BD families, investigate the molecular underpinnings of BD by focusing on lithium responders, and identify genes involved in lithium response. Additionally, we will look at the cellular targets of lithium and the genetics behind the side-effects that arise from treatment.

Lithium
=======

Lithium is a metallic salt most commonly known for its role in treating BD. Though it was first shown to have medical applications in the 1840s, for the treatment of bladder stones and gout, it was not until the late 19th century that the therapeutic effects of lithium in BD became recognized, and its use made mainstream by John Cade in 1949 \[[@B5]\]. Mogens Schou is credited with performing the first series of systematic trials with BD patients during the 1950s and 1960s and proving the short-term and prophylactic efficacy of lithium \[[@B6]\]. Lithium has been widely prescribed in the treatment of BD, based on the results of these studies as well as the high success rate - approximately 30% of patients show full response and 60% show partial response \[[@B2],[@B7],[@B8]\].

In recent decades, the use of lithium has declined in several Western countries, particularly the United States \[[@B9],[@B10]\]. This is probably due to the availability of other treatments on the market as well as concerns about side-effects of lithium, including its narrow therapeutic range. However, in spite of the side-effects, mounting evidence places lithium as one of the most efficient prophylactic interventions for BD \[[@B11]\].

Heritability of response to lithium
===================================

Like other psychiatric disorders, BD is highly heterogeneous in terms of symptoms and treatment efficacy. Factors shown to lead to disease susceptibility are varied and could be both environmental and genetic. Understanding the molecular biology behind symptoms as well as the mode of action of lithium treatment is important, though complicated in light of the aforementioned heterogeneity. In an effort to refine the BD sub-phenotype, response to lithium treatment has been shown to be a useful characteristic in molecular genetic studies. Lithium responders are identifiable BD patients based on several common attributes, such as episodic course of illness, low rates of co-morbid conditions, absence of rapid cycling, and a family history of BD \[[@B12],[@B13]\]. The outcome of treatment can be predicted upon initial presentation of symptoms based on several clinical factors, such as absence of residual symptoms and polarity of the first episode \[[@B3],[@B14],[@B15]\], as well as absence of psychiatric co-morbidity \[[@B15]\]. Conversely, psychiatric co-morbidity predicts poorer response to lithium \[[@B14]-[@B16]\]. This sub-phenotype shows greater genetic loading and familial heritability, which led to a variety of studies focusing on the families of patients with positive response to lithium treatment.

Most \[[@B17]-[@B19]\], though not all \[[@B20]-[@B23]\], of the family studies investigating the relationship between lithium responders and family history of BD have confirmed an association between increased frequency of BD among relatives and positive response to lithium. The stronger genetic loading for BD in lithium responders was first suggested by Mendlewicz *et al.*in 1973 \[[@B24]\], and later replicated by other studies \[[@B17],[@B25],[@B26]\]. These reports have also revealed very low rates of other psychiatric disorders among relatives of lithium-responder patients \[[@B17],[@B19],[@B27]\], and familial clustering was shown by Grof *et al.*\[[@B28]\]. The mode of inheritance of lithium-responsive BD in families, as reported by Alda *et al.*\[[@B29],[@B30]\], seems to be autosomal recessive with sex-specific penetrances; relatives of lithium responders are more likely to favorably respond to treatment with lithium should they develop BD symptoms. All of the characteristics mentioned distinguish lithium responders from patients who respond better to other mood stabilizers or who do not respond well to treatment, which strengthens the evidence for a higher genetic loading for this sub-phenotype \[[@B19],[@B31]-[@B33]\].

Genetic studies
===============

Susceptibility loci
-------------------

Linkage studies of BD have identified over 40 chromosomal susceptibility regions \[[@B34]-[@B44]\]; however, no clear susceptibility genes were identified through these genome scans, and in fact, meta-analyses showed no statistical significance to support a stronger susceptibility conferred by any one particular locus \[[@B45],[@B46]\]. Since the phenotypic heterogeneity of the disorder is probably at fault for the lack of agreement between studies, some groups have resorted to using more homogenous phenotypes - such as lithium response - as a selection criterion. Turecki *et al.*\[[@B27]\] suggested, in a genome scan of 31 families ascertained through probands with excellent lithium response, that chromosomal regions 15q14 and 7q11.2 could be involved in the pathogenesis of BD. Further analysis according to lithium response suggested that the locus on chromosome 7 may be implicated in lithium response, while the locus on chromosome 15 associates with the BD phenotype \[[@B27]\]. Other studies following a similar pharmacogenetic strategy include a haplotype-sharing analysis involving chromosomal region 18q23 carried out in a lithium-responsive founder effect population from the Faroe Islands \[[@B47]\], and a study on families from a homogenous population from Saguenay-Lac-St-Jean, Quebec, involving chromosomal region 12q23-q24 \[[@B37],[@B48]\]. In spite of the susceptibility regions found by these studies, no specific genes have been identified as involved in lithium-responsive BD. A strategy in bridging this gap is to correlate broad-scale findings of specific disease-associated loci with lithium\'s targets in the various cellular pathways.

Genome-wide association studies
-------------------------------

In the era of genome-wide association studies (GWASs), a large variety of loci significant for BD can be found using high-throughput genotyping technology. Recently, the Psychiatric GWAS Consortium has reported having access to 10 GWAS samples available or in preparation for BD, for a total of over 7,000 cases and 10,000 controls \[[@B49]\]. Loci that were most significantly implicated in these association studies are those mapping to or close to genes involved in neurotransmitter transport, biosynthesis and receptor activity, regulation of synaptic transmission, excitability and nervous system development, amino acid metabolism and chemotaxis. These represent approximately 240 genes, but unfortunately most are not replicated between studies \[[@B50],[@B51]\].

Several GWASs have been published to date \[[@B52]-[@B58]\], but the majority focused on BD in general and not lithium response. However, notably in the study by Baum *et al.*\[[@B53]\], the authors found the strongest result to be related to genetic variation in the diacylglycerol kinase (*DGKH*) gene, which encodes a key protein in the lithium-sensitive phosphatidyl inositol pathway. An attempt to replicate these findings was recently reported by Squassina *et al.*\[[@B59]\] in a Sardinian sample of 197 cases and 300 controls: the authors looked specifically for association between three *DGKH*single nucleotide polymorphisms (SNPs) and the BD phenotype. Additionally, 97 of the cases were characterized as excellent responders to lithium treatment, so association with the lithium-responsive sub-phenotype was also queried. Unfortunately, neither the associations previously shown by Baum *et al.*\[[@B53]\], nor the expected association with lithium response in BD could be validated by this study. Negative results could be attributed to the lack of power given by a relatively small sample size, as well as phenotypic heterogeneity between different populations \[[@B59]\]. This is particularly true in light of the fact that a similar replication study by Ollila *et al*. \[[@B60]\] performed in a larger sample size from Finland was able to confirm six SNP associations from the Baum *et al*. \[[@B53]\] or the Wellcome Trust Case Control Consortium \[[@B54]\] - one of these confirmed associations involved *DGKH*.

In a very recent article, Perlis *et al*. \[[@B61]\] described the first GWAS of response to lithium in BD. The authors genotyped 1.4 million SNPs in 1,177 BD patients of which 458 were treated with lithium, and further tried to replicate the most significant associations in a second cohort of 359 lithium-responder BD patients. Though no SNP was significant enough for genome-wide association, the study pointed to several chromosomal regions and candidate genes. Of note is the gene for the glutamate/alpha-amino-3-hydroxy-5-methyl-4-isoxazolpropionate (AMPA) receptor, *GRIA2*\[[@B61]\], which has previously been shown to be downregulated by chronic lithium treatment in a human neuronal cell line \[[@B62]\]. Though the authors\' strategy was inspired, problems such as heterogeneity of sample and gaps in clinical information, as well as a relatively limited sample size should be addressed in order to increase the success of future studies of this nature.

Molecular targets of lithium and candidate-gene studies
-------------------------------------------------------

The phosphoinositide pathway is one of the first and most studied cellular processes where lithium plays an inhibitory role. Berridge *et al.*first suggested this pathway in what is known as the \'inositol depletion hypothesis\' \[[@B63],[@B64]\]. According to this theory, lithium inhibits two enzymes in this pathway: inositol monophosphatase (IMPA) and inositol polyphosphate 1-polyphosphatase (INPP1) \[[@B64]\]. Klein and Melton \[[@B65]\] were the first to identify another target of lithium\'s inhibitory role in glycogen synthase kinase 3-beta (GSK3b). This enzyme is involved in the Wnt signaling pathway, where its inhibition facilitates β-catenin\'s role in promoting the activation of components involved in cell survival \[[@B66]\]. Some studies reported a SNP of the *GSK3b*gene as a source of variability between bipolar patients \[[@B67],[@B68]\], although this was not corroborated by all sources \[[@B69]\]. Interestingly, a study by Adli *et al.*\[[@B70]\] showed that acutely depressed individuals who were resistant to antidepressant treatment and who were carriers of the C allele of this SNP responded significantly better to lithium augmentation.

The cAMP (cyclic adenosine monophosphate) pathway is another target of lithium treatment, where the drug has been shown to play a role in regulating *CREB*(cAMP-response-binding-protein) activity \[[@B71]\]. Most studies propose that lithium decreases the phosphorylation of CREB, which interferes with expression of the genes regulated by the transcription factor \[[@B72]-[@B74]\], while others suggest that lithium also targets the CREB co-activator TORC1 (transducer of regulated CREB) \[[@B75]\]. The cAMP pathway seems to be affected by lithium at additional levels, including the stimulatory G-protein, protein kinase A \[[@B76],[@B77]\], and protein kinase C \[[@B62],[@B78]\].

Additional to these primary pathways of interest, several other candidate genes have been suggested, due to their location downstream of cellular factors regulated by lithium. Amongst them are the gene for phospholipase C gamma1 (*PLCG1*) \[[@B79]\], glycophorin A (*GYPA*) \[[@B80]\], the serotonin transporter gene (*SLC6A4*) and tryptophan hydroxylase (*TPH1*) \[[@B81],[@B82]\], as well as genes in the mitochondrial electron transport chain \[[@B83]\].

Gene expression studies
=======================

Microarrays
-----------

The development of microarray technology has allowed the study of expression patterns for a large number of genes simultaneously, providing invaluable information on gene regulation. Sun *et al.*\[[@B84]\] investigated the effect of chronic lithium treatment on cultured lymphoblasts from BD patients with excellent lithium response and found several genes that were downregulated when compared to control subjects. Among these were the genes alpha1B-adrenoceptor (*ADRA1B*), acetylcholine receptor protein alpha chain precursor (*CHRNA1*), cAMP-dependent 3\', 5\'-cyclic phosphodiesterase 4D (*PDE4D*), substance P-receptor (*SPR*), and the ras-related protein RAB7. A microarray profiling study of human neuronal cells after long-term treatment with lithium found that 347 transcripts were upregulated and 324 transcripts were downregulated. Of these, the most significant upregulation was found in peroxi redoxin 2 (*PRDX2*), encoding an antioxidant enzyme, and the most significant downregulation in tribbles homolog 3 (*TRIB3*), encoding a pro-apoptotic protein \[[@B62]\]. In a more recent study, Plant *et al*. \[[@B85]\] took a similar approach by looking at the effect of lithium on gene expression in human neuroblastoma cells. They found that therapeutic levels of lithium caused 14 statistically significant changes in gene expression in the cell line \[[@B85]\].

Model organisms
---------------

Model organisms have recently been used in gene profiling studies in order to elucidate the mode of action of lithium and possibly identify more of its targets. A microarray profiling study of mice subjected to daily lithium intake was reported by McQuillin *et al.*\[[@B86]\] and found 121 genes to be differentially expressed as a result of lithium treatment. Of these, three genes were most significantly inhibited at the transcriptional level: alanine-glyoxylate amino transferase 2-like 1 (*AGXT2L1*), c-mer proto-oncogene tyrosine kinase (*MERTK*), and sulfotransferase family 1A phenol-preferring member 1 (*SULT1A1*) \[[@B86]\]. A similar study by Chetcuti *et al.*\[[@B87]\] identified different genes with decreased expression in lithium-treated mice as compared to non-treated animals. Some examples are alpha1 poly-peptide (*ATP1A1*), transcription elongation factor B (SIII)-polypeptide 2 (*TCEB2*), proteasome subunit beta type 5 (*PSMB5*), and guanine nucleotide binding protein beta1 (*GNB1*) \[[@B87]\]. In rats, Bosetti *et al*. \[[@B88]\] found that oral lithium administration at both 7 and 42 days reduced the brain expression of a significant number of genes, many of which code for receptors, protein kinases, transcription and translation factors, and markers of energy metabolism and signal transduction \[[@B88]\].

The studies above did not report consistent results with regard to the genes showing highest differential expression; however, the results overlap in detecting members of the lithium-regulated pathways already discussed earlier in this review. Gene expression profiling studies, such as the ones mentioned here, are essential in addition to GWASs of bipolar disorder patients because they can provide the link between association and causation in disease etiology, as well as response to treatment.

Side-effects of lithium treatment
=================================

As part of the heterogeneity of BD, not all patients respond well to lithium treatment, and even the patients who are positive responders often develop side-effects. Of note are toxic renal effects such as nephrogenic diabetes insipidus (NDI) \[[@B89]-[@B91]\], which seem to be mediated through the inhibition of GSK3β, one of lithium\'s best characterized targets \[[@B92]\]. Developmental defects are caused by lithium in invertebrates, as shown in the offspring of rats \[[@B93]\] and mice \[[@B94]\] treated with lithium during pregnancy. In human pregnancies, early reports suggested strong teratogenic effects; however, more recent re-evaluation showed that the effects are dose-dependent and could be lessened by controlling lithium intake during pregnancy and within a short period prior to delivery \[[@B95]\]. Another significant side-effect is weight gain, which has a variety of long-term implications on the wellbeing of the patient \[[@B96]\].

Some studies have looked at side-effects in relation to a possible molecular genetic basis to explain the observed heterogeneity of side-effects between patients. An example is hypothyroidism, seen with long-term treatment, which McQuillin *et al*. \[[@B86]\] linked to lithium intake at the cellular level by showing that there were changes in mRNA expression in five genes related to thyroxine metabolism. Of these, the most significant were deiodinase (*DIO3*) and thyroid hormone receptor interactor 12 (*TRIP12*) \[[@B86]\].

Monitoring of patients at the beginning of treatment is very important to ensure correct dosage and to prevent renal problems, but this must be maintained regularly in order to prevent problems that may develop in the long term. Undoubtedly lithium\'s stabilizing benefits for patients far outweigh the problems. However, in some cases, the inconvenience of side-effects leads to treatment non-compliance, which in turn leads to complete reversal of symptoms and suicidal behavior \[[@B97]\].

Conclusions
===========

In spite of any side-effects, lithium is still recognized as the most effective prophylactic agent for BD. Moreover, continued treatment with lithium has been associated with a significantly reduced risk of suicide in patients with mood disorders \[[@B98]\], which appears to be unique to this line of treatment. While lithium\'s positive effect on BD symptoms is well accepted, the mechanisms leading to this response are only partially understood.

Future studies looking at the cellular pathways that are altered, as well as the genes upstream and downstream of these pathways, will be necessary. While the wealth of BD-related and psychiatric disorder-related research in recent years has identified many targets of lithium at the cellular and molecular levels, even more questions have been raised by these findings. It is clear that patients with positive response to lithium treatment can be separated into a subgroup based on symptoms as well as an increased level of genetic heritability of bipolar-spectrum disorders along first-degree family lines. By elucidating the mechanism of action of lithium and the genetic variants associated with the lithium-response sub-phenotype of BD, we will come closer to understanding disease etiology as a whole. Research focusing on this subgroup of bipolar disorders will be invaluable in the future to devise better treatment for those who do not respond well to lithium or any other drug that is currently available.
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